To cite this paper use one of the standards below:
The blood-brain barrier (BBB) plays a critical role in maintaining central nervous system homeostasis by regulating the passage of molecules between the bloodstream
and the brain. In Alzheimer's disease (AD), one of the most prevalent neurodegenerative disorders, increasing evidence suggests that the BBB becomes
compromised, contributing to disease progression. The relationship between BBB dysfunction and Alzheimer’s pathology is intricate, and changes in the barrier’s
integrity may exacerbate cognitive decline. Alzheimer’s disease is characterized by the accumulation of amyloid-beta (Aβ) plaques and tau tangles, which correlate with
neuronal damage and cognitive impairment. These pathological proteins not only affect neurons but also have a detrimental impact on the BBB. The breakdown of the
BBB allows the infiltration of harmful molecules and cells while also impairing the clearance of neurotoxic substances such as Aβ. This bidirectional disruption
exacerbates neuroinflammation, oxidative stress, and vascular dysfunction—key features of AD progression. Recent research has identified several critical molecular
players in BBB impairment in AD, including endothelial cell dysfunction, pericyte loss, and altered tight junction proteins. These changes lead to increased BBB permeability
and may precede the clinical symptoms of dementia. Additionally, age-related changes and genetic factors, such as the presence of the ApoE4 allele, further
increase susceptibility to BBB damage in Alzheimer’s patients. In response to the growing understanding of the BBB's importance in AD and other neurodegenerative
diseases, our laboratory has focused on developing in vitro models for studying the BBB. These models involve co-cultures of endothelial cells, astrocytes, and neurons
in static and dynamic setups. Our static BBB model is based on the transwell system, while the dynamic model is an innovative, in-house-developed microfluidic device.
Through these systems, we aim to develop more complex in vitro models to study sporadic AD, the most common form of the disease, representing approximately 95%
of all cases. By elucidating the mechanisms linking BBB dysfunction and neurodegeneration, we aim to enhance understanding of the vascular component of
AD.
This work was supported by CNPq (#406258/2022-8), FAPESP (#2018/12605-8), and CAPES (#001).
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper